Biogen Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Adams Diversified Equity Fund Inc. Acquires 56,000 Shares of Biogen Inc ...

📈 Adams Diversified Equity Fund Inc. increased its Biogen holdings by 126.4% in Q1, adding 56,000 shares to reach a total of 100,300 shares.

💰 The fund's position in Biogen is now valued at $18,388,000 as of the end of the reporting period.

📊 Other institutional investors including WPG Advisers LLC and Accredited Wealth Management LLC also increased their stakes in recent quarters.

🏦 Institutional ownership of Biogen stands at 87.93% according to current filing data.

🔍 UBS Group upgraded Biogen to a 'buy' rating with a price target of $225.00, while Royal Bank of Canada raised its target to $227.00.

⚖️ Cantor Fitzgerald restated an 'overweight' rating on the stock in a recent research report.

📉 Sanford C. Bernstein and Truist Financial reduced their price objectives to $200.00 and $189.00 respectively.

🎯 The consensus analyst rating is 'Moderate Buy' with an average price target of $217.37.

📈 Biogen reported Q1 EPS of $3.57, beating the consensus estimate of $2.95 by $0.62.

💵 Revenue for the quarter reached $2.48 billion, surpassing the $2.29 billion analyst expectation.

📈 Year-over-year revenue growth was 1.9% compared to the same period last year.

🛡️ The company maintains a strong balance sheet with a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

🔮 Biogen set FY 2026 EPS guidance between $14.25 and $15.25, slightly above the average analyst forecast of $13.95.

🧬 The firm focuses on therapies for neurological diseases including multiple sclerosis, Alzheimer's, and spinal muscular atrophy.

📉 Biogen's stock price has a 12-month low of $121.05 and a high of $218.06 with a current market cap of $31.89 billion.

Bullish Signals
  • Adams Diversified Equity Fund Inc. significantly increased its position by 126.4% in Q1, adding 56,000 shares to a total holding of 100,300 shares valued at $18.388 million.
  • Biogen reported quarterly earnings per share of $3.57, which topped analyst consensus estimates of $2.95 by $0.62.
  • The company generated revenue of $2.48 billion in the quarter, exceeding the consensus estimate of $2.29 billion.
  • Revenue grew 1.9% year-over-year compared to the same quarter last year.
  • UBS Group upgraded Biogen from a 'neutral' rating to a 'buy' rating and raised its price target to $225.00.
  • Royal Bank of Canada increased its price target on Biogen from $222.00 to $227.00 with an 'outperform' rating.
  • Cantor Fitzgerald restated an 'overweight' rating on the stock in a recent research report.
  • The company maintains a strong liquidity position with a current ratio of 3.06 and a quick ratio of 2.41.
  • Biogen's debt-to-equity ratio is low at 0.34, indicating a conservative capital structure.
  • FY 2026 guidance of $14.25-$15.25 EPS exceeds the average analyst expectation of $13.95.
Risk Factors
  • Sanford C. Bernstein cut its price objective on Biogen from $201.00 to $200.00 in a recent report.
  • Truist Financial reduced its price objective from $193.00 to $189.00 and set a 'hold' rating on the stock.
Full Analysis
Adams Diversified Equity Fund Inc. significantly increased its position in Biogen Inc. (NASDAQ:BIIB) by 126.4% in the first quarter, acquiring an additional 56,000 shares to hold a total of 100,300 shares valued at $18.388 million. This move joins other institutional investors like Reflection Asset Management and WPG Advisers LLC who also established or expanded their holdings in the biotechnology firm during recent quarters. Analyst sentiment remains mixed but generally positive regarding Biogen's valuation. Major firms including UBS Group upgraded the stock to a 'buy' rating with a price target of $225, while Royal Bank of Canada raised its target to $227. Conversely, Sanford C. Bernstein and Truist Financial lowered their price objectives slightly, resulting in a consensus 'Moderate Buy' rating and an average price target of $217.37. Biogen recently reported strong quarterly financial results that exceeded analyst expectations. The company posted earnings per share of $3.57 against a consensus estimate of $2.95, with revenue reaching $2.48 billion versus the expected $2.29 billion. Revenue grew 1.9% year-over-year, and the firm maintains robust liquidity with a current ratio of 3.06 and a market capitalization of $31.89 billion. Looking ahead, Biogen has provided fiscal year 2026 guidance ranging between $14.25 and $15.25 in earnings per share, which slightly exceeds the average analyst expectation of $13.95. The company continues to focus on its portfolio of therapies for neurological conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, supported by a strong balance sheet with low debt-to-equity leverage.